Bladder-Sparing cancer combo shows promise in early trial

NCT ID NCT01495676

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 26 times

Summary

This study tested whether adding gemcitabine to standard chemoradiation (cisplatin plus radiation) could help people with muscle-invasive bladder cancer avoid bladder removal. It included 69 adults with cancer that had not spread. The goal was to see if the new combination improved how long patients lived without their cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CRLC GF Leclerc

    Dijon, 21000, France

  • CRLC Val d'Aurelle-Paul Lamarque

    Montpellier, 34000, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Francois Baclesse

    Caen, 14000, France

  • Centre azuréen de Cancérologie

    Mougins, 06250, France

  • Clinique Patseur

    Toulouse, 31300, France

  • HEGP

    Paris, 75015, France

  • Hopital Henri Mondor

    Créteil, 94010, France

  • Hopital saint Louis

    Paris, 75010, France

  • Institut Bergonié

    Bordeaux, 33000, France

  • Institut de Cancérologie Lucien Neuwirth

    Saint-Priest-en-Jarez, 42705, France

Conditions

Explore the condition pages connected to this study.